Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: An interim report

Clinical Lung Cancer

Volumn 3, Issue 2, 2001, Pages 125-132

  Movsas, Benjamin ^a   Hudes, Richard S ^b   Schol, Jessie ^a   Millenson, Michael ^a   Rosvold, Elizabeth ^a   Nicolaou, Nicholas ^a   Litwin, Samuel ^a   Wang, Hao ^a   Keenan, Eileen ^a   Curran, Walter J ^c   Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Carboplatin; G CSF; Induction chemoradiation; Paclitaxel; Thoracic radiotherapy

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; LORAZEPAM; ONDANSETRON; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PERFORMANCE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0035214295     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2001.n.023     Document Type: Article

References (40)

1. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis
2. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group
3. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis
4. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer
5. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma
6. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
7. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
8. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
9. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer
10. Induction cisplatin/vinblastine and irradiation vs. Irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group
11. Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data
12. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results
13. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer
14. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer
15. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined Cooperative Oncology Group trial
16. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
17. Paclitaxel (P) by 1 or 24 hour (HR) infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma (NSCLC): A comparative analysis
18. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer
19. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
20. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer
21. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: A University of Colorado Cancer Center study
22. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center study 94-001
23. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
24. Sequential vs. Concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410)
25. A quality-adjusted time without symptoms or toxicity (QTWiST) analysis of Radiation Therapy Oncology Group (RTOG) 94-10
26. Initial report of Locally Advanced Multimodality Protocol (LAMP): ACR 427: A randomized 3-arm phase II study of paclitaxel (T), carboplatin non-small cell lung cancer (NSCLC)
27. Taxol: A novel radiation sensitizer
28. In vitro studies of Taxol as a radiation sensitizer in human tumor cells
29. Investigation of taxol as a potential radiation sensitizer
30. Sequential phase II studies of paclitaxel +/- carboplatin and radiation therapy (+/- hyperfractionation HFXRT) for locally advanced non-small cell lung cancer (NSCLC): Multiinstitutional trials
31. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): Three year follow-up
32. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium phase II trial
33. Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy
34. Daily paclitaxel (P) and radiotherapy (RT) in patients (Pts) with locally advanced non-small cell lung cancer (NSCLC). A phase I study
35. Seven-week continuous infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung cancer: A phase I study
36. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with nonoperative therapy
37. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer
38. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy
39. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified phase I/II trial
40. Gemcitabine with concurrent 3d conformal radiation followed by consolidation gemcitabine plus cisplatin; a phase I trial for patients with stage III non-small cell lung cancer (NSCLC)